Getting the diagnosis of chronic myeloid leukemia, Bud
Interviewee: Bud. Bud recounts receiving the diagnosis that he had chronic myeloid leukemia. (DNAi Location: Applications > Genes and medicine > Drug design > Bud's Story > "A death sentence")
It was devastating there I didn't know what to do, you know, that's a death sentence. Was then. It was a death sentence. They gave me two or three years is what he gave me and that was eight years ago. I've been into it five now out of eight. So I beat it by five so far but of course that's, you know what it is, Gleevecâ„¢ there has helped me out.
chronic myeloid leukemia,location applications,gleevec,dnai,romine,death sentence,cml,interviewee,leukemia,bud,genes,diagnosis,medicine
- ID: 15041
- Source: DNALC.DNAi
Related Content
15042. The first day of clinical trials for Gleevec, Bud and Yvonne
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
15043. Bloodcount returns to normal with Gleevec, Bud and Yvonne
CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevec⢠inhibits the molecular cause of chronic myeloid leukemia.
15056. Approval for Gleevec in record time, Brian Druker
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
15994. The chronic myeloid leukemia (CML) mutation
View the animation to learn about the Philadelphia chromosome, the abnormal chromosome that causes chronic myeloid leukemia.
1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1
Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.